Candidate Clinical Correlate of Prognostic Outcome for TB Study

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Jun 4, 2025

Keywords

ClinConnect Summary

The Candidate Clinical Correlate of Prognostic Outcome for TB (C3PO) study is part of a larger research effort aimed at improving how we predict the risk of tuberculosis (TB) coming back after treatment. This study is looking for new ways to identify patients who might be at risk for recurring TB by testing different samples, like sputum (mucus from the lungs) and blood. Currently, the tools we use to predict the chance of TB returning are not very effective, so finding better methods could help in developing new treatments and improving patient care.

If you or someone you know is over the age of 12 and has successfully completed treatment for drug-susceptible TB with a standard six-month medication plan, you may be eligible to participate. However, if treatment was completed more than 14 days ago or if you have taken any medications that fight TB in the last 14 days for reasons unrelated to TB treatment, you cannot join the study. Participants will be asked to attend follow-up visits and will need to provide consent to be part of this important research. This trial is actively recruiting participants, and everyone, regardless of gender, is welcome to apply.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. . individuals age ≥ 12 years;
• • 2. . have completed treatment for drug-susceptible tuberculosis with the standard 6-month regimen of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE).
• Exclusion Criteria:
• • 1. completed treatment for drug-susceptible tuberculosis \>14 days prior to screening/enrollment;
• • 2. routinely taking any medication with anti-mycobacterial activity (including fluoroquinolones) for any reason not related to tuberculosis treatment within the last 14 days;
• • 3. unwilling to provide informed consent or return for study follow-up visits.